Drug Discovery – Talk Bio

Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact

5 days ago talkbio0Tagged biobucks, biotech partnership, Cardiovascular Diseases, Drug Discovery, Flagship, Novartis, pharmaceutical milestones, ProFound Therapeutics, Proteomics

Novartis; ProFound Therapeutics; cardiovascular disease; biotech partnership; drug discovery; proteomics; biobucks; flagship pioneering; pharmaceutical milestones

Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Biological Science Disciplines, Clinical Trials, Drug Discovery, Efficiency, Financial cost, Infrequent, R&D, trends qualifier

AI in life sciences; R&D efficiency; drug discovery; clinical trials; pharma innovation; 2025 AI trends; cost reduction; rare diseases

Fauna Unveils ‘Fauna Brain’: An Agentic AI System Accelerating Drug Discovery with Proven Results in Lilly Collaboration

2 weeks ago talkbio0Tagged agentic AI, Aortic Valve Insufficiency, Brain, Comparative Genomics, Drug Discovery, Lilly collaboration, multi-agent system, Pharmaceutical Research

Fauna Brain; agentic AI; drug discovery; comparative genomics; Lilly collaboration; multi-agent system; pharmaceutical research; AI platform

Illuminating the CKD Patient Journey: Clinicogenomic Data Reshapes Research & Drug Discovery

2 weeks ago talkbio0Tagged Cell Therapy, Chronic Kidney Diseases, Clinical Trials, clinicogenomics, Drug Discovery, gene therapy, Precision Medicine

chronic kidney disease; CKD; clinicogenomics; drug discovery; cell therapy; gene therapy; clinical trials; personalized medicine

AstraZeneca and CSPC Enter $5.3B AI-Driven Drug Discovery Pact in China

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China, Chronic disease, Dosage Forms, Drug Discovery, GZMH gene, Investments, oral therapies, Partnership, R&D, research

AstraZeneca; CSPC Pharmaceutical; AI research; drug discovery; chronic diseases; China; $5.3 billion; oral therapies; partnership; R&D investment

AstraZeneca Signs $110M AI-Driven R&D Deal with CSPC Pharmaceutical for Chronic Disease Drugs

3 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China pharma, Chronic disease, Collaboration, Dosage Forms, Drug Discovery, Drug Industry, GZMH gene, Immune System Diseases, milestone payments, oral therapies

AstraZeneca; CSPC Pharmaceutical; AI drug discovery; chronic diseases; immunological diseases; oral therapies; R&D collaboration; China pharma; milestone payments; pharmaceutical industry

NVIDIA and Novo Nordisk Partner to Accelerate AI-Driven Drug Discovery

3 weeks ago talkbio0Tagged AI models, Artificial Intelligence, BioNeMo, Drug Discovery, Gefion AI Supercomputer, Nordisk, NVIDIA, Omniverse, pharmaceutical innovation

NVIDIA; Novo Nordisk; AI models; drug discovery; Gefion AI Supercomputer; BioNeMo; Omniverse; pharmaceutical innovation

Novo Nordisk Signs $812M Deal with Deep Apple to Develop Non-Incretin Obesity Drugs

3 weeks ago talkbio0Tagged cardiometabolic disease, Deep Apple, Drug Discovery, G-Protein-Coupled Receptors, Non-Incretin, Nordisk, Obesity, research collaboration, Small Molecule

Novo Nordisk; Deep Apple Therapeutics; obesity; non-incretin; GPCR; cardiometabolic disease; small molecules; research collaboration; deal; drug discovery

Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs

3 weeks ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, biotech collaboration, Drug Development, Drug Discovery, Eli, Eli Lilly, muscle health, Muscle-Boosting Drugs, Obesity, stem cell-secreted proteins

Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal

MIT’s Boltz-1 AI Model Rivals AlphaFold 3 in Biomolecular Structure Prediction

4 weeks ago talkbio0Tagged AlphaFold, Aortic Valve Insufficiency, Artificial Intelligence, biomolecular structure prediction, Boltz-1, Drug Discovery, MIT, open-source AI, protein folding

MIT; Boltz-1; AlphaFold 3; AI model; biomolecular structure prediction; drug discovery; protein folding; open-source AI